



HAL
open science

Substitution of unsaturated lipid chains by thioether-containing lipid chains in cationic amphiphiles: physicochemical consequences and application for gene delivery

Amal Bouraoui, Mathieu Berchel, Rosy Ghanem, Véronique Vie, Gilles Paboef, Laure Burel-Deschamps, Olivier Lozach, Tony Le Gall, Tristan Montier, Paul-Alain Jaffres

► To cite this version:

Amal Bouraoui, Mathieu Berchel, Rosy Ghanem, Véronique Vie, Gilles Paboef, et al.. Substitution of unsaturated lipid chains by thioether-containing lipid chains in cationic amphiphiles: physicochemical consequences and application for gene delivery. *Organic & Biomolecular Chemistry*, 2019, 17 (14), pp.3609-3616. 10.1039/c9ob00473d . hal-02088106

HAL Id: hal-02088106

<https://hal-univ-rennes1.archives-ouvertes.fr/hal-02088106>

Submitted on 14 Jun 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ARTICLE

Substitution of unsaturated lipid chains by thioether containing lipid chains in cationic amphiphiles: physico-chemical consequences and application for gene delivery.

Amal Bouraoui,^a Mathieu Berchel,^a Rosy Ghanem,^c Véronique Vié,^b Gilles Paboeuf,^b Laure Deschamps,^a Olivier Lozach,^a Tony Le Gall,^c Tristan Montier^c and Paul-Alain Jaffrès^{*a}

The hydrophobic moiety of cationic amphiphiles plays an important role in the transfection process because its structure has an impact on both the type of the supramolecular assembly and the dynamic properties of these assemblies. These latter have to exhibit a compromise between stability and lability to efficiently compact then deliver DNA into target cells. In the present work, we report the synthesis of new cationic amphiphiles featuring a thioether function at different positions of two 18-atoms length lipid chains and we study their physicochemical properties (anisotropy of fluorescence, compression isotherms) with analogues possessing either oleyl (C18:1) or stearyl (C18:0) chains. We show that the fluidity of cationic lipids featuring a thioether function located close to the middle of each lipid chain is intermediate with that of oleyl- and stearyl-containing analogues. These properties are also supported by the compression isotherms assays. When used as carriers to deliver a plasmid DNA, thioether-containing cationic amphiphiles demonstrate a good ability to transfect human-derived cell lines, those incorporating such a moiety in the middle of the chain being the most efficient. This work supports the use of a thioether function as a possible alternative to unsaturation in aliphatic lipid chains of cationic amphiphiles to modulate physicochemical behaviours and in turn biological activities such as gene delivery ability.

Introduction

Cationic amphiphilic compounds, formulated as a liposomal solution, have the ability to interact spontaneously with nucleic acids and to compact them into cationic nanoparticles (lipoplexes). These aggregates have the capacity to cross the cell plasma membrane and to deliver nucleic acids into the cytoplasm.¹ Such nanoparticles demonstrated noticeable interests for different *in vitro* and *in vivo* applications including the transfection of cultured cells mimicking pathologic situations², lung transfection,³ vaccination⁴ or tendon healing.⁵ Synthetic carriers such as cationic lipids can be synthesized on large scale and according to the Good Manufacturing Practices (GMPs). Furthermore, their use for *in vivo* applications does not induce any immune response in animal and human hosts, thus permitting repeated administrations.⁶ In our group, we have developed straightforward syntheses (in 2 to 4 steps) of bio-inspired lipophosphoramidates,⁷ lipothiophosphoramidates⁸ or lipophosphates.⁹ Besides the polar headgroup and the linker, - the lipid moiety was identified as a crucial parameter determining the interaction with DNA. However, if DNA

compaction is usually required for gene delivery, too much stable lipoplexes typically yield low transfection efficiencies as observed for instance with amphiphiles incorporating stearyl (C18:0) lipid chains.¹⁰ The incorporation of unsaturation or ramification (phytanyl chains¹¹ or synthetically branched lipid chains¹²) within the hydrophobic moiety disturbs the packing of the lipid chains which in turn is correlated with low temperature fused lipid phase and higher transfection efficiencies. It was suggested that a subtle balance between stability (needed before cell internalization) and instability (required after internalization by endocytosis)¹³ of the lipoplexes has to be reached. The lipid moiety plays a central role to tune this balance. One possibility consist to place an unsaturation within the lipid chains (e.g. oleyl chains). However, alkene of Z configuration may present some chemical instability¹⁴. Therefore, it is worth exploring other hydrophobic domains that would be chemically stable and devoid of chirality to design new nucleic acid carriers.

Here, our attention focused on the incorporation of a thioether non polar functional group within the hydrophobic domain of cationic amphiphilic compounds. The use of thioether function was reported by Dobner et al. for the synthesis of bolaphospholipids featuring a central lipid chain where two methylene units were replaced with either two oxygen or two sulfur atoms.¹⁵ Molecular modelling pointed out that the incorporation of thioether groups induced two kinks in the lipid chains likely explained by the replacement of the all-trans

^a CEMCA UMR CNRS 6521, Université de Brest, IBSAM, 6 Avenue Victor Le Gorgeu, F-29238 Brest, France. Mail : pjaffres@univ-brest.fr.

^b Univ Rennes, CNRS, IPR - UMR 6251, ScanMAT - UMS 2001, F-35000 Rennes.

^c INSERM UMR 1078, Université de Brest, IBSAM, UFR Médecine et Sciences de la Santé, CHRU Brest, 22 avenue Camille Desmoulins, F-29238 Brest, France.

† Footnotes relating to the title and/or authors should appear here.

Electronic Supplementary Information (ESI) available: [details of synthesis procedures, CAC determination, liposomal solution characterization]. See DOI: 10.1039/x0xx00000x




Figure 2 Synthesis of the cationic amphiphiles **4a-d**.

conformation characterized by CCC bond angle of 113.3° by CSC bond angles of 96.1° . A second study, investigated the incorporation of thioether function within the structure of ionic liquids.¹⁶ It was shown that the replacement of one methylene unit of a C18:0 alkyl chain by a thioether function induced a drastic reduction of the melting point attesting important supramolecular modifications. Moreover, melting point values depended on the position of the thioether function in the alkyl chain underlying an impact at the supramolecular level. Therefore, the present study aims to design cationic amphiphilic compounds in which the Z-C=C double bond of the oleyl chain (which is likely the most used for the design of cationic amphiphiles used for nucleic acids delivery) is replaced by a thioether function within a straight (non-branched) hydrophobic domain. Additionally, taking into account the paper of O'Brien *et al.*¹⁶ that assessed the influence of the position of the thioether function on the physico-chemical properties, we report herein the synthesis of the compounds **4a-d** (Figure 1) characterized with a thioether function at different positions in the lipid chains. Two additional cationic amphiphiles were included in this study for comparison purposes. They incorporated either two mono-unsaturated oleyl (C18:1) lipid chains (**BSV36**) or two saturated stearic (C18:0) alkyl chains (**BSV101**). The six compounds shown in Figure 1 thus featured exactly the same number of atoms (18 atoms) in their backbone lipid chains whereas the polar head group and the spacer are rigorously identical. This homogenous series of compounds permitted relevant comparisons of both physico-chemical properties and transfection activities allowing to clearly address the potential impact of thioether function within lipid chains of cationic amphiphiles.

Results and discussion

The synthesis of compounds **4a-d** starts by the synthesis of the dialkyl phosphites possessing in ω -position of the alkyl chain one unsaturation (Figure 2). These compounds **1a-d** were prepared according to two methods. The first one is based on the reaction of allyl alcohol or pent-4-en-1-ol with PCl_3 followed by a hydrolysis step.¹⁷ The second method, that requires a non-volatile alcohol, is based on the reaction of alcohol with diphenylphosphite under reduced pressure which is needed to eliminate phenol (a side-product of this reaction) by sublimation. These phosphites **1a-d** were then engaged in an Atherton-Todd's reaction¹⁸ with *N,N*-dimethylethylenediamine to produce the phosphoramidate **2a-d**. The third step consisted in the quaternarization of these compounds with methyl iodide to produce, in good yields, the cationic amphiphiles **3a-d**. The last step, make use of the photo-click thiol-ene reaction triggered by UV and using 2,2-Dimethoxy-2-Phenylacetophenone (DMPA) as radical initiator. Accordingly, alkyl thiols of different lengths were selected to produce at the end the cationic amphiphiles **4a-d** each possessing 18 atoms in their backbone lipid chains (spectroscopic data of compounds **4a-d** are available in ESI 1).

The Critical Aggregation Concentration (CAC) of compound **4a-d** was determined by fluorescence (using the Nile red as fluorescent probe¹⁹). Compounds **4a-d** feature similar value (around 1 to 2×10^{-5} mol/L) as for **BSV101** and **BSV36** (ESI 2). Then, all the compounds were formulated as a liposomal solution at 1.5 mM in water by using the lipid film hydration method. Interestingly, we found that it was possible to prepare liposomal solutions with these new cationic amphiphiles after a




Figure 3 Compression isotherms for compounds **4a-d** and compounds **BSV101** and **BSV36**.

Table 1 : compression isotherms - main data.

	Lift-off value - A ₀ Å ² /molecule	Surface area at the collapse Å ² /molecule	Pressure at the collapse mN/m
4a	140	50	50
4b	110	40	47
4c	180	60	47
4d	180	45	47
BSV36	160	75	47
BSV101	80	45	58

A₀: Minimal molecular surface area at a pressure of 0 mN/m (lift-off values)

relatively short hydration time (i.e. 18h), especially when compared with branched lipid chains-containing amphiphiles (which synthesis was previously reported by using thiol-ene click reaction and that required 3 days of hydration before their formulation as liposomal solution).¹² Dynamic Light Scattering (DLS) measurements indicated that liposomal solutions of **4a-d** exhibited average sizes from 75 to 94 nm with close polydispersity indexes (0.24 to 0.34). Of note, the smaller liposomes were observed for the compounds for which the thioether function was closer to the polar head group. The zeta potential measurements indicated positive charges from +37 to +62 mV which are typical of liposomes prepared from cationic amphiphiles (ESI 3).

Then, we further assessed the supramolecular behaviour of the compounds **4a-d** by recording the compression isotherms at the air/water interface (figure 3). These experiments give

information relative to the propensity of the cationic amphiphiles to cover water surface and the pressure needed to compact the amphiphiles up to the collapse that corresponds to the destruction of a monolayer. Since all the compounds possess an identical polar head group, the difference of behaviour arises only from the different structures of the hydrophobic domain. The minimal mean molecular area (Å²/molecule) corresponding to pressure of 0 mN/m (lift-off values noted A₀) is a first indication of the supramolecular organization of the hydrophobic domain (Table 1). In this regard, **BSV101** (featuring saturated alkyl chains) exhibits the lower A₀ value (80 Å²/molecule) that can likely be explained by the fact that the alkyl chains are partly in all-*trans* conformation, thus reducing the surface area. The addition of one unsaturation (**BSV36**) or a thioether function (**4a-d**) increases the A₀ value from 110 (**4b**) to 180 (**4c** and **4d**) Å²/molecule in comparison with **BSV101**. The compounds **4c**, **4d** and **BSV36** are those featuring the highest A₀ value and can therefore be considered as the compounds with the most disordered lipid chains in absence of applied pressure. The second significant point is the molecular area at the collapse pressure that indicates how the molecules can be packed together before producing interfacial multi-lamellar packing or aggregates diving in the water phase. To this respect, the presence of unsaturations (**BSV36**) is a structural feature that induces a collapse at higher mean molecular area indicating that the volume occupied by the oleyl chains is higher than for the other lipid chains considered herein. On the other hand, the compounds **4a-d** feature a small surface area at the collapse (from 40 (**4b**) to 60 (**4c**) Å²/molecule) indicating that the volume of the lipid domain is smaller and/or that these lipid chains can produce a regular packing leading to a small surface area. It can be noted that in absence of pressure compounds **4c-d** occupy high surface area whereas in presence of pressure they can self-organized in a dense packing pointing out a capacity to adapt their conformation depending on the constrains. Finally, the pressure at the collapse is an indication of the robustness of the supramolecular packing. In this regard, the absence of unsaturation or thioether function close to the middle of the lipid chain produces the most robust supramolecular packing (**4a** and **BSV101**; 50 and 58 mN/m). All the other compounds featured a lower value for the pressure at the collapse at 47 mN/m (Table 1) indicating that the robustness of the monolayer is globally identical for **BSV36**, **4b**, **4c** and **4d**. Simultaneously to the surface ellipsometric angle (Δ, °) was recorded during the compression isotherms using a home-made ellipsometer, in the so-called “null-ellipsometer configuration”. The ellipsometric angle (Δ) depends on two parameters, the reflexion index and the thickness of the lipid film. The reflexion index is considered constant during compression permitting to consider Δ as a function of the film thickness.²⁰ As shown in the Supporting Materials (ESI 4), in absence of pressure the compounds **4c** and **4d** produced the thinner monolayer (lower value of Δ) whereas **BSV101** produced the thicker monolayer. These results are fully consistent with the lift-off values (Table 1).




Figure 4 Anisotropy measurements of compounds **4a-d** and the reference compounds **BSV101** and **BSV36** formulated as liposomal solution at 0.2 mM.

Then, fluorescence anisotropy was used to probe the viscosity of the supramolecular packing of amphiphilic compounds. For that purpose, diphenylhexatriene (DPH) was used as a hydrophobic fluorescent probe. This probe is known to be localized within the hydrophobic region and inform on the dynamic process as previously reported for other amphiphilic compounds.^{2,21} As reported in Figure 4, the structure of the lipid chain deeply impacts their supramolecular dynamics. Indeed, the saturated C18 lipid chain (**BSV101**) features a transition from gel to fluid phase at the highest temperature (50°C). This observation is also in agreement with the pressure at the collapse, which was the more intense for **BSV101** (Table 1). The incorporation of a thioether function decreases the values of the main transition (T_m) with a great influence of its position within the lipid chain. Indeed, compound **4a** features a transition at 35°C whereas the three other compounds **4b-d** feature almost a similar T_m between 16 to 19 °C. These results are again consistent with the pressure at the collapse since the more robust monolayer (**4a**, **BSV101** ; Table 1) features the highest T_m . Finally, the presence of one unsaturation per lipid chain or a thioether group indicates that the T_m is even lower in presence of an oleyl chain (**BSV36** ; $T_m < 0^{\circ}\text{C}$). However, at physiological temperature (37°C), the thioether containing amphiphiles **4b-d** and the unsaturated compound **BSV36** feature almost similar anisotropy. The fluidity of the compounds **4a-d** is likely due to the presence of the sulfur atom that prevents a close packing of the molecules. The bigger size of sulfur atom and the induction of a bend in the hydrophobic chain due to the bond angle and bond length involving the sulfur atom are the two parameters that likely account for the fluidity at lower temperature. This bend was determined using molecular modeling. As detailed in the supporting material (ESI 5), a bend of 175.6° was estimated by molecular modelling for the lipid chains present in molecules **4a-d**. Next, we recorded for one sample (**4d**) ³¹P NMR (Hahn echo sequence) spectra to further study the supramolecular organization.²² It must be noted that the reference compound **BSV36** produced in similar hydration state a layered packing.¹² The ³¹P NMR spectrum of compound **4d** (hydrated at a concentration of 100 mg/mL)




Figure 5 Transfection efficacies (TE) of the different cationic amphiphiles **4a-d** and the two references **BSV101** and **BSV36** at Charge Ratio 4 (CR=4) for two cell lines (A549 and 16HBE). Free DNA is used as a negative control. A luciferase-encoding plasmid DNA was used in these experiments (pGM144 ; 0.25 µg/well). TE was determined 24 h after deposition. Results are expressed as the Relative Light Units/mg of total proteins obtained with each formulation, reflecting their transfection abilities, as the mean \pm SD of 3 wells.

indicates that this compound adopts also a layered supramolecular packing as attested by both the symmetry of the signal (the most intense peak σ_{\perp} is on the right hand side of the pattern) and the chemical shift anisotropy ($\Delta\sigma > 40$ ppm) (ESI 6).¹²

Then, the capacity of compounds **4a-d** to transfect two human-derived cell lines (i.e. A549 and 16HBE) was assessed at different charge ratios (CR); the latter corresponds to the number of positive charges belonging to the cationic amphiphiles divided by the number of negatives charges coming from the nucleic acids. Since the best transfection efficacies were generally measured at CR=4 (see the full data in the ESI 8), the transfection efficacies at that CR for compounds **4a-d** and the two references (**BSV101**, **BSV36**) are provided for comparison in figure 5 (the reference compound **BSV36** used in this series of assays was previously compared to Lipofectamine).¹⁰ In agreement with previous investigations, saturated alkyl chains (**BSV101**) are detrimental to transfection efficacies likely due to a too robust supramolecular packing as shown by compression isotherms and fluorescence anisotropy. For A549 cell line, the transfection assays were repeated with a lower quantities of plasmid (0.1 µg/well) and the trend was similar since the best transfection efficacies were obtained at CR=4 and the most efficient cationic amphiphiles were compounds **4c** and **4d** (ESI 7). The incorporation of a thioether function within the lipid chain can have a positive impact on the transfection efficacies, depending on the position of this function within the hydrophobic chain. A thioether group close to the polar head group (phosphoramidate function) has only a weak positive effect on the transfection efficacy (compounds **4a** and **4b**). On contrary, a thioether function in the middle of the hydrophobic domain (at position 10 or 12) produces efficient gene carriers (compounds **4c** and **4d**). Interestingly, cationic amphiphiles bearing thioether-containing lipid chains yield similar or even better efficacies (depending on the cell line considered) when compared with structural analogues featuring unsaturated lipid chains (i.e. oleyl chains, which are present in **BSV36** as well as in a large

number of cationic amphiphiles commonly used for gene delivery purposes). It is interesting to notice that the most efficient compounds **4c-d** combined three identical indicators (T_m below 20°C; pressure at the collapse below 48 mN/m; lift-off pressure A₀ > 150 mN/m). Then, the cell viability was assessed by a bioluminescent method (quantification of ATP) or MTT assays (ESI 8). 80% of viability was globally observed at CR=4 (the most efficient CR) and a higher tolerance was observed for compound 4d (ESI 8). Altogether, we can conclude that the thioether containing amphiphiles, and especially compound 4d, have a weak side effect on the viability and that this viability is similar to those observed with BSV36 (cationic amphiphiles possessing two oleyl chains). Noteworthy, all these experiments (transfection and viability) were carried out with the cationic amphiphiles formulated alone. The incorporation of co-lipids within the formulations or the use of other strategies recently reported could reduce the side toxic effects.²³ These results show that the incorporation of thioether function within the lipid chain is an interesting strategy to produce gene carriers. The two most efficient carriers reported herein (**4c** and **4d**) have a thioether function located close to the middle of each lipid chain.

Experimental

A Material

All commercial reagents were used as received. Solvent were dried with a MBRAUN Solvent Purification Systems (SPS-800 series). ¹H, ¹³C, ³¹P NMR were recorded on Bruker spectrometers (300, 400 or 500 MHz). Chemical shift δ are express in ppm and the abbreviation used are s (singlet), d (doublet), t (triplet), q (quadruplet). Mass spectra was recorded on Bruker MALDI-TOF autoflex III ; 2,5-Dihydroxybenzoic acid (DHB) was used as matrix. Fluorescence was recorded on Agilent Cary Eclipse Fluorescence Spectrophotometer, using automatic polarizers for anisotropy measurements. Size and zeta measurement were achieved with a MALVERN Nano ZS. **BSV36** and **BSV101** were synthesised as previously reported.²⁴

B Synthesis.

Synthesis of compounds 1a and 1b: (the protocol was adapted from T. W. Kassa *et al.*, [Error! Bookmark not defined.](#)) in a 500 mL two neck round bottom flask fitted with an addition funnel, phosphorus trichloride (1 equivalent) was dissolved in 150 mL of dry toluene and cooled at 10°C. A mixture containing two equivalents of either allyl alcohol (for the synthesis of **1a**) or pent-4-en-1-ol (for the synthesis of **1b** (2 eq.) and triethylamine (2 eq.) was added slowly over a period of 1 h. under vigorous stirring. The resulting mixture was allowed to warm to room temperature (rt) and one additional equivalent of either allyl alcohol or pent-4-en-1-ol was added. Then the reaction was stirred overnight at rt. Triethylamine hydrochloride precipitate was removed by filtration over celite and washed several times with toluene. The organic layer was washed with water (100 mL) and then dried over Na₂SO₄, filtered and concentrated to give a colorless oil.

1a (x g ; Yield 97 %) : ¹H NMR (400 MHz, CDCl₃): δ= 4.48-4.51 (m, 4H), 5.17-5.32 (m, 4H), 5.81-5.85 (m-2H), 5.92-7.68 (d, ¹J_{HP} 703

Hz, 1H); ³¹P{¹H} NMR (162 MHz, CDCl₃): δ= 8.3; ¹³C{¹H} NMR (75 MHz, CDCl₃): δ= 65.2, 117.5, 130.4.

1b (x g ; Yield 98%): ¹H NMR (400 MHz, CDCl₃): δ= 1.71-1.75 (m, 4H), 2.05-2.11 (m,4H), 3.97-4.03 (m-4H), 4.91-4.99 (dd, 4H), 5.67-5.74 (m, 2H), 5.86-7.59 (d, ¹J_{HP} 692 Hz, 1H); ³¹P{¹H} NMR (CDCl₃, 162 MHz): δ= 8.4; ¹³C{¹H} NMR (75 MHz, CDCl₃): δ= 28.29-29.07, 66.47, 115.16, 136.53.

Synthesis of compound 1c-d: non-8-en-1-ol (undecen-1-ol) (2 eq.) and diphenyl phosphite (1 eq.) were combined and treated by Kugelroch distillation under reduced pressure for 3 h at 130°C to remove phenol. The expected product, that doesn't distill, was obtained as colorless oil.

1c (x g ; Yield 91%): ¹H NMR (400 MHz, CDCl₃): δ= 1.39-1.48 (m, 16H), 1.75-1.79 (m, 4H), 2.01-2.13 (m, 4H), 4.12-4.18 (m, 4H), 4.99-5.10 (m, 4H), 5.83-5.93 (m-2H), 6.02-7.75 (d, ¹J_{HP} 692 Hz); ³¹P{¹H} NMR (162 MHz, CDCl₃): δ= 8.4.

1d (x g ; Yield 96%): ¹H NMR (400 MHz, CDCl₃): δ= 1.24-1.33 (m, 24H), 1.62-1.66 (m, 4H), 1.96-2.02 (m, 4H), 4.01-4.05 (m, 4H), 4.86-4.97 (m, 4H), 5.71-5.81 (m-2H), 5.89-7.63 (d, ¹J_{HP} 695 Hz); ³¹P{¹H} NMR (162 MHz, CDCl₃): δ= 8.4.

General protocol for the synthesis of compounds 2a-d: To a solution of compound **1** (1 eq. ; 2.56x10⁻³ mol) in 20 mL CH₂Cl₂ was added *N,N*-dimethylethylenediamine (1.1 eq), DIPEA (1.1 eq) and BrCCl₃ (1.1 eq) at 0°C. The reaction was stirred for 15 min. at 0°C then for 4 h. at rt. The solvent was evaporated and 30 mL of diethylether were added and the mixture was stirred for 10 min. then filtered, and the solvent evaporated. The residue was dissolved in 20 mL of CH₂Cl₂, washed with water, dried over MgSO₄ filtered and concentrated. The compound was purified by silica gel chromatography using CH₂Cl₂/MeOH: 90/10 (v/v) as eluant to produce a colorless oil.

2a (Yield 40%): ¹H NMR (400 MHz, CDCl₃): δ= 2.46 (s, 6H), 2.73 (t, J=6.0 Hz, 2H), 3.09-3.12 (m, 2H), 4.04-4.07 (m, 1H), 4.46-4.50 (m, 4H), 5.87-5.95 (m, 2H); ³¹P{¹H} NMR (CDCl₃, 162 MHz) δ= 10.1;

2b (Yield 52%): ¹H NMR (400 MHz, CDCl₃): δ= 1.63-1.67 (m,4H), 1.99-2.04 (m,4H), 2.09 (s, 6H), 2.59 (t, J= 6 Hz, 2H), 2.81-2.85 (m, 2H), 3.34-3.37 (m,1H), 3.84-3.87 (m, 4H), 4.83-4.92 (dd, 4H), 5.61-5.71 (m, 2H); ³¹P{¹H} NMR (162 MHz; CDCl₃) δ= 10.2.

2c (Yield 60%): ¹H NMR (400 MHz, CDCl₃): δ=1.24-1.31(m, 16H), 1.58-1.61 (m, 4H), 1.94-1.98 (m, 4H) 2.16 (s, 6H), 2.32 (t, J= 6.2 Hz, 2H), 2.87-2.95 (m, 2H) 3.27-3.31 (m, 1H), 3.89-3.98 (m, 4H), 4.84-4.94 (m, 4H), 5.68-5.76 (m, 2H); ³¹P{¹H} NMR (162 MHz; CDCl₃) δ= 9.9.

2d (Yield 72%): ¹H NMR (400 MHz, CDCl₃): δ= 1.11-1.20 (m, 24H), 1.45-1.51 (m, 4H), 1.83-1.88 (m, 4H), 2.04 (s, 6H), 2.21 (t, J=6.0 Hz, 2H), 2.75-2.82 (m, 2H), 3.31-3.37 (m, 1H), 3.78-3.81 (m, 4H), 4.72-4.83 (m, 4H), 5.56-5.62 (m, 2H). ³¹P{¹H} NMR (CDCl₃, 162 MHz) δ= 10.2.

General synthesis of compound 3a-d: to a solution of **2** (1 eq.; 2x10⁻³ mol) in CH₂Cl₂ (20 mL) was added methyl iodide (4 eq.) and the reaction was stirred overnight at rt. The solvent and the excess of methyl iodide were evaporated to give a clear yellow salt.

3a (Yield 92%): ¹H NMR (400 MHz, CDCl₃): δ= 3.42 (s, 9H), 3.44-3.52 (m, 2H), 3.79 (t, J=6.0 Hz, 2H), 4.46-4.49 (m, 4H), 4.81-4.95

(m, 1H), 5.19-5.35 (m, 4H), 5.85-5.95 (m, 2H). $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , 162 MHz) $\delta=9.0$.

3b (Yield 92%): ^1H NMR (400 MHz, CDCl_3): $\delta=1.63$ -1.67 (m, 4H), 1.99-2.04 (m, 4H), 3.46 (s, 9H), 3.54-3.55 (m, 2H), 3.85 (t, $J=5.6$ Hz, 2H), 3.84-3.87 (m, 4H), 4.47-4.50 (m, 1H), 4.83-4.92 (m, 4H), 5.61-5.71 (m, 2H). $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz; CDCl_3) $\delta=9.1$.

3c (Yield 96%): ^1H NMR (400 MHz, CDCl_3): $\delta=1.27$ -1.35 (m, 16H), 1.60-1.64 (m, 4H), 1.97-2.02 (m, 4H), 3.34 (s, 9H), 3.44-3.50 (m, 2H), 3.81 (t, $J=6.0$ Hz, 2H), 3.91-3.96 (m, 4H), 4.42-4.45 (m, 1H), 4.87-4.97 (m, 4H), 5.72-5.79 (m, 2H); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) $\delta=8.8$.

3d (Yield 95%): ^1H NMR (400 MHz, CDCl_3): $\delta=1.26$ -1.35 (m, 24H), 1.61-1.68 (m, 4H), 1.89-2.05 (m, 4H), 3.46 (s, 9H), 3.52-3.56 (m, 2H), 3.84 (t, $J=6.0$ Hz, 2H), 3.94-3.99 (m, 4H), 4.39-4.41 (m, 1H), 4.90-5.01 (m, 4H), 5.74-5.84 (m, 2H). $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , 162 MHz) $\delta=8.9$.

General protocol for the synthesis of compound 4a-d: compound **3** (1 eq, 1.6×10^{-3} mol) alkane thiol (4 eq.) and 2,2-dimethoxy-2-phenylacetophenone (0.4 eq.) were placed in a schlenk tube and degassed under argon for 10 min. The mixture was then placed under UV lights at rt for at least 4 h. The product was purified with silica gel chromatography using $\text{CH}_2\text{Cl}_2/\text{MeOH}$: 90/10 (v/v) as eluent phase to give the desired compounds as a yellow salt.

4a (BSV-S4 ; yield 58%): ^1H NMR (400 MHz, CDCl_3): $\delta=0.85$ (t; $J=6.8$ Hz, 6H), 1.23-1.34 (m, 48H), 1.50-1.56 (m, 4H), 1.91-1.94 (m, 4H), 2.48 (t, $J=7.2$ Hz, 4H), 2.58 (t, $J=7.2$ Hz, 4H), 3.44 (s, 9H), 3.54-3.55 (m, 2H), 3.83 (t, $J=5.4$ Hz, 2H), 4.07-4.11 (m, 4H), 4.62-4.64 (m, 1H); $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , 162 MHz) $\delta=8.9$; $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75 MHz): $\delta=13.6$ ($\text{CH}_3\text{-CH}_2$), 22.1-31.6 (CH_2 fatty chain, S- CH_2) 35.6 ($\text{CH}_2\text{-NH-P}$), 54.3 ($\text{CH}_3\text{-N}^+$), 65.0 ($\text{CH}_2\text{-N}^+$), 66.2 (d, $\text{CH}_2\text{-O-P}$); MALDI-TOF (matrix: DHB): $[\text{M}]^+$ calculated for $\text{C}_{39}\text{H}_{84}\text{N}_2\text{O}_3\text{PS}_2 = 723.566$; observed $[\text{M}]^+ = 723.667$.

4b (BSV-S6 ; yield 62%) ^1H NMR (400 MHz, CDCl_3): $\delta=0.86$ (t, $J=7$ Hz, $\text{CH}_3\text{-CH}_2$, 6H). 1.26-1.35 (m, CH_2 , 40H), 1.52-1.59 (m, 8H). 1.63-1.66 (m, 4H), 2.48 (t, $J=7.0$ Hz, $\text{CH}_2\text{-S}$, 8H). 3.46 (s, 9H), 3.56 (m, 2H), 3.94-3.98 (m, 2H), 4.37-4.40 (m, 1H); $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , 162 MHz) $\delta=8.9$; $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75 MHz): $\delta=13.6$ ($\text{CH}_3\text{-CH}_2$), 22.18- 31.7 (CH_2 fatty chain, S- CH_2), 35.6 ($\text{CH}_2\text{-NH-P}$), 54.3 ($\text{CH}_3\text{-N}^+$), 66.2 ($\text{CH}_2\text{-N}^+$), 66.4 (d, $\text{CH}_2\text{-O-P}$); MALDI-TOF (matrix: DHB): $[\text{M}]^+$ calculated for $\text{C}_{39}\text{H}_{84}\text{N}_2\text{O}_3\text{PS}_2 = 723.566$; observed $[\text{M}]^+ = 723.708$.

4c (BSV-S10 ; yield 48%): ^1H NMR (400 MHz, CDCl_3): 0.85 (t, $J=6.2$ Hz, 6H), 1.36 (m, 40H), 1.45-1.49 (m, 4H), 1.51-1.53 (m, 4H), 1.55-1.60 (m, 4H), 1.62-1.69 (m, 4H), 2.46-2.52 (m, 8H), 3.46 (s, 9H), 3.54-3.55 (m, 2H), 3.85 (t, 5.6 Hz, 2H), 3.96-4.01 (m, 4H), 4.47-4.50 (m, 1H); $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , 162 MHz) $\delta=8.8$; $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75 MHz): $\delta=13.6$ ($\text{CH}_3\text{-CH}_2$), 22.1- 31.7 (CH_2 fatty chain, S- CH_2) 35.6 ($\text{CH}_2\text{-NH-P}$), 54.4 ($\text{CH}_3\text{-N}^+$), 66.2 ($\text{CH}_2\text{-N}^+$), 66.7 (d, $\text{CH}_2\text{-O-P}$); MALDI-TOF (matrix: DHB): $[\text{M}]^+$ calculated for $\text{C}_{39}\text{H}_{84}\text{N}_2\text{O}_3\text{PS}_2 = 723.566$; observed $[\text{M}]^+ = 723.703$.

4d (BSV-S12 ; yield 55 %) : ^1H NMR (400 MHz, CDCl_3): $\delta=0.86$ (t, $J=7$ Hz, 6H). 1.26-1.35 (m, 4H), 1.52-1.59 (m, 8H). 1.63-1.66 (m, 4H), 2.48 (t, $J=7.4$ Hz, 8H). 3.46 (s, 9H), 3.56 (m, 2H), 3.94-3.98 (m, 2H), 4.37-4.40 (m, 1H); $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , 162 MHz) $\delta=8.9$; $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75 MHz): $\delta=13.6$ ($\text{CH}_3\text{-CH}_2$), 22.18- 31.7 (CH_2 fatty chain, S- CH_2) 35.6 ($\text{CH}_2\text{-NH-P}$), 54.4 ($\text{CH}_3\text{-N}^+$), 66.2 ($\text{CH}_2\text{-N}^+$),

66.76 (d, $\text{CH}_2\text{-O-P}$); ; Maldi TOF (matrix: DHB): $[\text{M}]^+$ calculated for $\text{C}_{39}\text{H}_{84}\text{N}_2\text{O}_3\text{PS}_2 = 723.566$; observed $[\text{M}]^+ = 723.723$.

B Compression isotherms and ellipsometry.

The Langmuir trough was vigorously cleaned with ethanol and water then it was filled with the sub-phase (water). A good base line in the ($\pi\text{-A}$) isotherm indicated the cleanliness of the interface. The cationic lipid in $\text{CHCl}_3/\text{MeOH}$ (2/1) mixture (25 μL) was slowly spread at the air-water interface using a Hamilton microliter syringe. After evaporation of the solvents, the isotherm of the lipid monolayer was measured by compressing the barriers at the rate of 5 cm^2/min . The surface pressure was measured using a filter paper held by a Wilhelmy balance connected to a microelectronic feedback system. The experiment was stopped once the collapse was reached.

Simultaneously, the ellipsometric angle was recorded during the compression. The values of Delta (Δ , $^\circ$) were reported in ESI8. Δ_{min} correspond to the value obtained at the lift off of the molecule (when the surface pressure began to increase) while Δ_{max} correspond to the collapse point.

B CMC and anisotropy.

The fluorescent probe 1,6-diphenylhexatriene (DPH) was used for anisotropy measurements whereas the solvatochromic fluorescent probe Nile red was used for CMC determination. Further details are present in ESI 9.

C Transfection efficacy and cell viability

DNA complexation: Lipoplexes were prepared by mixing pDNA (pEGFP-Luc, Clontech) with each liposomal solution in Opti-MEM (Gibco). Addition of luciferase encoding pGM144 (0.25 $\mu\text{g}/\text{well}$) to the liposomal solutions was performed at concentrations corresponding to CR.

Transfection efficacies: The *in vitro* reporter gene assay via the luciferase measurement was carried out as reported previously. Error! Bookmark not defined. In short, the two cell lines were grown in either EMEM (16HBE) or DMEM (A549) both supplemented with 10% fetal bovine serum, 1% antibiotic and 1% L-glutamine. All incubations were performed at 37°C in a humidified atmosphere containing 5% CO_2 . The day before transfection, the cells were seeded into a 96-well plate at a density of 25 000 cells per well. Lipoplexes were prepared as detailed above and then added dropwise to each well; the reference compound BSV 36 was used as a positive transfection control whereas naked DNA was used as a negative control. After 24 h. at 37°C, the culture medium was removed and the cells were lysed with Passive Lysis Buffer (Promega) prior to examination via a chemiluminescence assay (Luciferase Assay System, Promega) to determine the luciferase expression. The total protein content of each cell lysate was determined using the BC assay kit (Uptima). Finally, data were expressed as relative light units (RLU) per milligram of total proteins (mean \pm SD with $n=3$)

Cell viability: The cell viability was considered to estimate the toxicity resulting from the exposure of the cells to the lipoplexes and the transfection process. For 16HBE cell line we used the ViaLight kit (Lonza) was used to determine the ATP content which reflects the number of living cells (transfected or not) in culture, as a result of both cell proliferation and cell mortality

(either normal or experimentally-induced) that occurred during the 24 h. of the experiment. This assay was used as recommended by the manufacturer. The results were expressed as percentages relative to the viability of non-transfected cells used as the reference (100% cell viability). For A549, due to difficulties with the ViaLight kit, MTT assays was used following the manufacturer's recommendations

Conclusions

This study reports a simple procedure to incorporate in selective position of a hydrophobic chain a thioether function using photo-click thiol-ene coupling. Accordingly, a homogeneous series of compounds was prepared since the only variation point arises from the presence of a thioether function at different position. These four new compounds were compared with related compounds exhibiting either mono-unsaturated (oleyl chain) or fully saturated (C18-alkyl) lipid chains. The comparison of the compression isotherms, and fluorescence anisotropy led to the conclusion that the presence of thioether function close to the middle of the hydrophobic chains increase the fluidity of the supramolecular assemblies that can be interpreted as an increase of the disordered state of the lipid chains. The cationic amphiphiles **4c** and **4d** applied for gene delivery feature high transfection efficacies. The viability at the most efficient charge ratio is around 80% for both cationic amphiphiles indicating that further studies (e.g. association with helper lipid) will be needed to reduce toxicity. Nevertheless, the intrinsic physico-chemical features induced by the incorporation of thioether function in the structure of the lipid chain constitute a new possibility to tune the fluidity of supramolecular assemblies and for the design of other type of amphiphiles (zwitterionic, bola or anionic amphiphiles).

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank Vaincre La Mucoviscidose (Paris, France), AFM, association Gaétan Saleün (Brest-France), CNRS and INSERM for funding.

Notes and references

‡ Footnotes relating to the main text should appear here. These might include comments relevant to but not central to the matter under discussion, limited experimental and spectral data, and crystallographic data.

- 1 a) T. Montier, T. Benvegno, P. A. Jaffrès, J. J. Yaouanc and P. Lehn, *Curr. Gene Ther.*, 2008, **8**, 296; b) M.A. Mintzer and E. Simanek, *Chem. Rev.*, 2009, **109**, 259; c) N. Belmani, P. Midoux, C. Pichon, P. Loyer, C. Passirani, T. Le Gall, P.A. Jaffrès, P. Lehn and T. Montier, *Biotechnol. J.*, 2015, **10**, 1370.
- 2 V. Laurent, A. Fraix, T. Montier, S. Cammas-Marion, C. Ribault, T. Benvegno, P. A. Jaffrès and P. Loyer, *Biotechnology J.*, 2010, **5**, 314-320.
- 3 T. Le Gall, D. Loizeau, E. Picquet, N. Carmoy, J.J. Yaouanc, L. Deschamps, P. Delépine, P. Giamarchi, P.A. Jaffrès, P. Lehn and T. Montier, *J. Med. Chem.*, 2010, **53**, 1496.
- 4 a) C. J. Wu, S. C. Lee, H. W. Huang and M. H. Tao, *Vaccine*, 2004, **22**, 1457-1464 ; b) F. Perche, T. Benvegno, M. Berchel, L. Lebegue, C. Pichon, P.A. Jaffrès and P. Midoux P. *Nanomedicine: NBM*, 2011, **7**, 445-453; c) A. Le Moignic, V. Malard, T. Benvegno, L. Lemiègre, M. Berchel, P.A. Jaffrès, C. Baillou, M. Delost, R. Macedo, J. Rochefort, G. Lescaille, C. Pichon, F.M. Lemoine, P. Midoux and V. Mateo, *J. Control. Release*, 2018, **278**, 110-121.
- 5 A. Delalande, M.P. Gosselin, A. Suwalski, W. Guilmain, C. Leduc, M. Berchel, P.A. Jaffrès, P. Baril, P. Midoux and C. Pichon. *Nanomedicine: NBM*, 2015, **11**, 1735-1744.
- 6 M.F. Lindberg, T. Le Gall, N. Carmoy, M. Berchel, S.C. Hyde, D.R. Gill, P.A. Jaffrès, P. Lehn and T. Montier, *Biomaterials*, 2015, **59**, 1-11.
- 7 M. Berchel, T. Le Gall, J.P. Haelters, P. Lehn, T. Montier and P. A. Jaffrès, *Mol. Pharm.*, 2015, **12**, 1902-1910.
- 8 A. Fraix, T. Montier, N. Carmoy, D. Loizeau, L. Burel-Deschamps, T. Le Gall, P. Giamarchi, H. Couthon-Gourvès, J. P. Haelters, P. Lehn, and P.A. Jaffrès, *Org. Biomol. Chem.*, 2011, **9**, 2422-2432
- 9 A. Fraix, T. Montier, N. Carmoy, D. Loizeau, L. Burel-Deschamps, T. Le Gall, P. Giamarchi, H. Couthon-Gourvès, J. P. Haelters, P. Lehn, and P.A. Jaffrès, *Org. Biomol. Chem.*, 2011, **9**, 2422-2432.
- 10 a) S. S. Le Corre, M. Berchel, T. Le Gall, J.P. Haelters, P. Lehn, T. Montier and P.A. Jaffrès, *Eur. J. Org. Chem.*, 2014, **36**, 8041-8048; b) S. S. Le Corre, N. Belmadi, M. Berchel, T. Le Gall, J.P. Haelters, P. Lehn, T. Montier and P.A. Jaffrès, *Org. Biomol. Chem.*, 2015, **13**, 1122-1132.
- 11 M. Lindberg, N. Carmoy, T. Le Gall, A. Fraix, M. Berchel, C. Lorilleux, H. Couthon-Gourvès, P. Bellaud, A. Fautrel, P.A. Jaffrès, P. Lehn and T. Montier, *Biomaterials*, 2012, **33**, 6240-6253.
- 12 D. Afonso, T. Le Gall, H. Couthon-Gourvès, A. Grélard, S. Prakash, M. Berchel, N. Kervarec, E.J. Dufourc, T. Montier and P.A. Jaffrès, *Soft Matter*, 2016, **12**, 4516-4520.
- 13 L. Billiet, C. Gonçalves, J.P. Gomez, J. Lodewick, M. Berchel, P.A. Jaffrès, T. Montier, P. Lehn, E. Bertrand, Y. El-Ghoul, H. Cheradame, P. Guégan, M. Mével, B. Pitard, T. Benvegno, C. Pichon, and P. Midoux, *Biomaterials*, 2012, **33**, 2980-2990.
- 14 L. Qiao, A. Ge, Y. Liang and S. Ye, *J. Phys. Chem. B.*, 2015, **119**, 14188-14199.
- 15 S. Drescher, A. Meister, G. Graf, G. Hause, A. Blume, and B. Dobner, B., *Chem. Eur. J.*, 2008, **14**, 6796-6804.
- 16 R. A. O'Brien, A. Mirjafari, K.M. Mattson, S.M. Murray, N. Mobarrez, E.A. Salter, A. Wierzbicki, J.H. Davis, and K.N. West, *J. Phys. Chem. B*, 2014, **118**, 10232-10239.
- 17 T. W. Kassa, N Zhang, A. F. Palmer. *Artificial Cells, Nanomedicine, and Biotechnology*, 2013; 41: 109-115.
- 18 S.S. Le Corre, M. Berchel, H. Couthon-Gourvès, J.P. Haelters, and P.A. Jaffrès, *Beilstein J. Org. Chem.*, 2014, **10**, 1166-1196.
- 19 M.C.A. Stuart, J.C. van de Pas, and J.B.F.N. Engberts, *J. Phys. Org. Chem.*, 2005, **18**, 929-934.
- 20 A. Jacquemet, V. Vié, L. Lemiègre, J. Barbeau, and T. Benvegno, *Chem. Phys. Lipids*, 2010, **163**, 794-799.
- 21 B.R. Lentz, *Chem. Phys. Lipids*, 1993, **64**, 99-116.
- 22 A. Grélard, P. Guichard, P. Bonnafous, S. Marco, O. Lambert, C. Manin, F. Ronzon and E. J. Dufourc, *FASEB J.*, 2013, **27**, 4316-4326.
- 23 Q. Huang, S. Li, Y.F. Ding, H. Yin, L.H. Wang and R. Wang, *Biomater. Sci.*, 2018, **6**, 1031-1039.

ARTICLE

Journal Name

- 24 S.S. Le Corre, M. Berchel, N. Belmadi, C. Denis, J.P. Haelters, T. Le Gall, P. Lehn, T. Montier and P.A. Jaffrès, *Org. Biomol. Chem.*, 2014, **12**, 1463-1474.